Thiotepa through an Ommaya reservoir for lung cancer spread to brain fluid
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests whether a chemotherapy drug called thiotepa, given directly through a small device in the scalp (called an Ommaya reservoir), can safely and effectively treat lung cancer that has spread to the fluid around the brain and spinal cord. It's for people whose cancer has stopped responding to standard EGFR-targeted pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old and have lung cancer (non-small cell) that has spread to the fluid around the brain and spinal cord.
- Your cancer must have stopped responding to EGFR-targeted pills (like erlotinib, gefitinib, or osimertinib), or you never had that mutation and your first treatment stopped working.
- You must already have an Ommaya reservoir — a small device placed under the scalp to deliver medicine directly into the fluid around the brain.
- You need to be reasonably active (able to care for yourself, though not necessarily for heavy tasks) and have stable cancer in the rest of your body.
- Your liver, kidneys, and bone marrow must be working well enough, and you must be willing to use birth control if there is any chance of pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a higher dose of an EGFR-targeted pill, either alone or with a chemotherapy drug injected into the fluid around the spinal cord, can control lung cancer that has spread to the lining of the brain (called leptomeningeal metastases). It is for people whose cancer has gotten worse in the brain lining while on a standard dose of this type of medication.
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.
This study tests whether a drug called pemetrexed, given directly into the fluid around your brain through a small implanted device, is safe and effective for treating lung cancer that has spread to the lining of the brain. It is for people whose cancer has a specific genetic change (EGFR, ALK, or ROS1) and who have already tried standard targeted pills that no longer control their disease.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
Hear when a new Leptomeningeal Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.